methylphenidate has been researched along with Depressive Disorder, Treatment-Resistant in 2 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, G | 1 |
| Brotchie, H | 1 |
| McClure, G | 1 |
| Fletcher, K | 1 |
| Chan, HN | 1 |
| Mitchell, PB | 1 |
| Loo, CK | 1 |
| Harvey, SB | 1 |
1 review available for methylphenidate and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Pharmacological treatment approaches to difficult-to-treat depression.
Topics: Anticonvulsants; Antidepressive Agents; Comorbidity; Depressive Disorder, Treatment-Resistant; Disea | 2013 |
1 other study available for methylphenidate and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefits.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Central Nervous System Stimulants; Cost-Benefit An | 2013 |